BofA analyst Tazeen Ahmad lowered the firm’s price target on Annexon (ANNX) to $11 from $12 and keeps a Buy rating on the shares. The firm rolled the quarter, updated for Q4 results, cash and share count, and adjusted operating expense estimates based on management commentary.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating
- Promising Developments in Annexon Biosciences’ Pipeline Drive Buy Rating
- Promising Potential of Annexon Biosciences’ ANX1502 Drives Buy Rating Amid Positive Clinical Data
- Annexon price target lowered to $20 from $30 at H.C. Wainwright
- Strategic Advancements and Financial Stability Drive Buy Rating for Annexon Biosciences